Substance Abuse Treatment Prevention and Policy
January 12, 2006
Sara Smucker Barnwell, Mitch Earleywine, Rand R. Wilcox
69 citations
Daily cannabis use does not impair motivation, and its impact on subjective wellbeing is small. A large sample of 487 people, comparing those who used cannabis daily with those who had never used it, found no differences in motivation using standard or robust statistical methods. A small difference in subjective wellbeing was detected only with robust methods, but this was largely accounted for by medical users reporting health problems, suggesting illness rather than cannabis use lowered wellbeing. All statistical tests failed to reach significance at the p = .05 level, indicating no reliable effects.
Substance Abuse Treatment Prevention and Policy
September 23, 2016
Ling‐yi Feng, Wenjing Yu, Wei-Ting Chang et al.
49 citations
Although methamphetamine remains a problem, new psychoactive substances (NPS) have become an emerging issue in both Taiwan and South Korea, though their patterns differ. Taiwan seizes much larger quantities of NPS, particularly ketamine, despite having far fewer controlled NPS items than Korea. These differences suggest the NPS come from different sources. Factors beyond geographical proximity, including drug policy and drug availability and accessibility, help explain the current status of illegal drug use in the two countries.
Substance Abuse Treatment Prevention and Policy
May 14, 2022
Victor Mocanu, Lindsay Mackay, Devon Christie et al.
27 citations
International drug policy is changing alongside promising evidence for psychedelic-assisted psychotherapy (PAP) to treat mental health conditions. Canada has expanded therapeutic access, reversing an 8-year ban on medical exemptions through the Special Access Programme in January 2022 and granting the first exemptions for legal possession and personal use of psilocybin mushrooms in 2020, nearly 50 years after criminalization. This piece clarifies factors for safely expanding access to psychedelics. Streamlining safe, evidence-based compassionate use of PAP could offer timely treatment options while encouraging further research and outcome surveillance to refine best practices.